According to U2's manager Paul McGuinness, the revolutionary and landmark method English band Radiohead used last fall to release the album In Rainbows was a failure and "backfired." Talking to the BBC, McGuinness critiqued the band and the "pay-what-you-like" method because it still resulted in over 60%-70% of listeners acquiring the album through illegal channels. He told the BBC that U2's forthcoming new album, due this fall, would not be released in a similar method at all.
The primary reason U2's album will not be released like Radiohead's In Rainbows, is probably because the Irish quartet is still contracted with Universal Music Group for album releases. Radiohead released In Rainbows without the assistance of a record label or any firm of the music industry. Their management and the band's website was utilized to oversee the release of the album. Perhaps McGuinness realized how much would be required for him if U2 chose that method? The new U2 album is due near the end of October, regardless.
McGuinness also told the BBC that physical sales "are still an enormous part of [U2's] business and [the band] still sell a lot of actual CDs." Although Radiohead did not release In Rainbows on CD in the beginning, when the CD appeared in January it went straight to number one in various countries, including the United States and the United Kingdom. The band has still not revealed exact figures from the experimental method, but that has not kept other groups and critics from analyzing it, including McGuinness. The U2 album will likely sell well, but that shouldn't mean that a download-only method initially was a failure.
Last updated: February 12, 2012: 08:43 PM
Hot Stocks
DailyFinance Headlines
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
Benzinga Headlines
- Michigan Consumer Sentiment Index Drops
- Don't Bank on Barclays
- GSV Capital Punished for Expanding Facebook Investment
- Chesapeake Gently Lets Go of Gas
- How to Profit off Addicts
TheFlyOnTheWall.com Headlines
- Milestone Aviation Group signs contract for three S-92 helicopters
- Greek parliament approves austerity bill, Reuters reports
- Xstrata shareholders want Glencore offer above three shares, Telegraph says
- France Telecom pursuing greater interest in Egypt's Mobinil, Bloomberg says
- Arab league to ask U.N. for a peacekeeping force in Syria, WSJ says
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- 4 Money-Etiquette Questions Answered
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
Walmart's New Health Food Push: Is It Too Hard to Swallow?
Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger

